respiratory syncytial virus

Ribavirin (Tribavirin) is a synthetic nucleoside analog of ribofuranose with activity against hepatitis C virus and other RNA viruses.

Fusion glycoprotein (92-106) [Human respiratory syncytial virus] is a peptide with the sequence H2N-Glu-Leu-Gln-Leu-Leu-Met-Gln-Ser-Thr-Pro-Pro-Thr-Asn-Asn-Arg-OH, MW= 1741.96.

Anti-Human respiratory syncytial virus (RSV) Fusion Glycoprotein RSV-F Antibody (1B191) is a Rabbit IgG monoclonal antibody targeting RSV Human respiratory syncytial virus (RSV) Fusion Glycoprotein RSV-F.

Ziresovir (RO-0529) is a respiratory syncytial virus fusion protein (RSV F) inhibitor that inhibits RSV activity and can be used in the study of syncytial virus sensing.

(R)-AZD 9639 is the R-isomer of AZD 9639, a novel respiratory syncytial virus (RSV) fusion inhibitor with antiviral activity.

YM-53403 is an antiviral activity that effectively inhibits the replication of RSV strains belonging to subgroup A and subgroup B. It can be used to treat respiratory syncytial virus infections.

Xibornol (Nanbacine) has broad-spectrum antibacterial and antiviral activity and can be used to study Gram-positive bacterial infections and human respiratory syncytial virus and human coronavirus 229E infections.

Enzaplatovir (BTA-585) is an orally available fusion inhibitor with antiviral activity for the study of respiratory syncytial virus infections and coronavirus disease (COVID-19) infections.

JNJ-49095397 (RV568) is a selective p38 MAPK-α and p38 MAPK--γ kinase inhibitor with anti-inflammatory activity and potential antiviral activity for chronic obstructive pulmonary disease (COPD), cystic fibrosis, and respiratory syncytial virus infection.

BTA-9881 is a novel RSV fusion inhibitor with oral activity and antiviral activity for the study of respiratory syncytial virus infections.

Roflumilast (APTA 2217) is an orally available, long-acting inhibitor of phosphodiesterase (PDE) type 4 (PDE4), with anti-inflammatory and potential antineoplastic activities. Upon administration, roflumilast and its active metabolite roflumilast N-oxide selectively and competitively bind to and inhibit PDE4, which leads to an increase of both intracellular levels of cyclic-3', 5'-adenosine monophosphate (cAMP) and cAMP-mediated signaling.

Rostafuroxin (PST 2238) has been used in trials studying the treatment of Essential Hypertension.

Amentoflavone (3',8''-Biapigenin), as a potent inhibitor of CYP3A4 and CYP2C9, can interact with many other medications. CYP3A4 and CYP2C9 are proteins used for drug metabolism in the body. Amentoflavone also is an inhibitor of human cathepsin B. It has antimalarial activity in trials significant affinities towards the Delta-1, kappa opioid receptors (as an antagonist) and binds to benzodiazepine receptors. Amentoflavone may be a potential lead for a new type of anti-inflammatory agents having the dual inhibitory activity of group II phospholipase A2 and cyclooxygenase. Amentoflavone and quercetin differentially exerted suppression of PGE2 biosynthesis via downregulation of COX-2 iNOS expression.

BMS-433771, a novel inhibitor of respiratory syncytial virus (RSV), binds the RSV F glycoprotein and inhibits membrane fusion.

Quercetin pentaacetate (Pentaacetylquercetin) has diverse biological activities, including antioxidant, anti-inflammatory, and anticancer properties. Quercetin pentaacetate interacts with RSV and inhibit the viral adhesion on cell surface.

RSV604 (A-60444) racemate, a racemic mixture, exhibits lower potency against strains of respiratory syncytial virus (RSV) compared to its S-isomer.

hRSV-IN-1 is an inhibitor of respiratory syncytial virus (hRSV).

RSV-IN-6 (Compound 53) is a specific inhibitor of the respiratory syncytial virus (RSV) that targets the M2-1 protein, demonstrating strong potency with EC50 values of 4.4 μM against RSV-A and 1.3 μM against RSV-B strains [1].

RSV-IN-3 (Compound 1) is a dual inhibitor targeting both the respiratory syncytial virus (RSV) and influenza virus A (IAV), with an anti-RSV efficacy demonstrated by an EC50 of 32.70 μM [1].

Gontivimab (ALX-0171) is a trivalent nanobody targeting the hRSV fusion (F) protein with anti-RSV antiviral properties for the study of respiratory syncytial virus infections.

GS-441524 was shown to be a safe and effective treatment for feline infectious peritonitis (FIP). The optimum dosage was found to be 4.0 mg kg SC q24h for at least 12 weeks

GS-441524tris-isobutyryl ester is a prodrug form of the antiviral nucleoside analog and remdesivir metabolite GS-441524 .1It reduces the cytopathic effect of respiratory syncytial virus (RSV) in infected HEp-2 cells with an EC50value of 0.26 μM. 1.Mackman, R.L., Hui, H.C., Perron, M., et al.Prodrugs of a 1'-CN-4-aza-7,9-dideazaadenosine C-nucleoside leading to the discovery of remdesivir (GS-5734) as a potent inhibitor of respiratory syncytial virus with efficacy in the african green monkey model of RSVJ. Med. Chem.64(8)5001-5017(2021)

Sekikaic acid is a phenolic lichen metabolite that has been found in H. obscurata and has diverse biological activities. It scavenges superoxide and DPPH radicals in cell-free assays when used at a concentration of 0.5 µM. Sekikaic acid is active against the rg recombinant strain of respiratory syncytial virus (RSV; IC50 = 5.69 µg ml). It inhibits the protein-protein interaction between mixed lineage leukemia 1 (MLL1) and the GACKIX domain of CREB-binding protein (CBP; IC50 = 34 µM).

EIDD-2749 (4'-FlU), a ribonucleoside analog, is an orally available RdRp inhibitor with spectroscopic antiviral activity that interrupts the replication of respiratory syncytial virus and SARS-CoV-2.EIDD-2749 attenuates lethal infections of pandemic human and highly pathogenic avian influenza viruses.